Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2013 Nov 11;8(11):e79636. doi: 10.1371/journal.pone.0079636

Hypoxia-Induced Changes in the Bioactivity of Cytotrophoblast-Derived Exosomes

Carlos Salomon 1,*, Miharu Kobayashi 1, Keith Ashman 1, Luis Sobrevia 1,2, Murray D Mitchell 1, Gregory E Rice 1
Editor: Cees Oudejans3
PMCID: PMC3823597  PMID: 24244532

Abstract

Migration of extravillous trophoblasts (EVT) into decidua and myometrium is a critical process in the conversion of maternal spiral arterioles and establishing placenta perfusion. EVT migration is affected by cell-to-cell communication and oxygen tension. While the release of exosomes from placental cells has been identified as a significant pathway in materno-fetal communication, the role of placental-derived exosomes in placentation has yet to be established. The aim of this study was to establish the effect of oxygen tension on the release and bioactivity of cytotrophoblast (CT)-derived exosomes on EVT invasion and proliferation. CT were isolated from first trimester fetal tissue (n = 12) using a trypsin-deoxyribonuclease-dispase/Percoll method. CT were cultured under 8%, 3% or 1% O2 for 48 h. Exosomes from CT-conditioned media were isolated by differential and buoyant density centrifugation. The effect of oxygen tension on exosome release (µg exosomal protein/106cells/48 h) and bioactivity were established. HTR-8/SVneo (EVT) were used as target cells to establish the effect (bioactivity) of exosomes on invasion and proliferation as assessed by real-time, live-cell imaging (Incucyte™). The release and bioactivity of CT-derived exosomes were inversely correlated with oxygen tension (p<0.001). Under low oxygen tensions (i.e. 1% O2), CT-derived exosomes promoted EVT invasion and proliferation. Proteomic analysis of exosomes identified oxygen-dependent changes in protein content. We propose that in response to changes in oxygen tension, CTs modify the bioactivity of exosomes, thereby, regulating EVT phenotype. Exosomal induction of EVT migration may represent a normal process of placentation and/or an adaptive response to placental hypoxia.

Introduction

Placentation is an oxygen sensitive process. The events that occur from the time of implantation to maternal perfusion of the placenta are influenced and directed by site-specific oxygen tensions [1]. At the time of embryo implantation, the intrauterine oxygen tension is ∼3% [2] while the decidua and myometrium oxygen tension is ∼8–12% [3]. This standing oxygen gradient is thought to promote and direct the invasion of extravillous trophoblast cells (EVT) into the decidua and myometrium where they engage and remodel maternal spiral arterioles [4], [5]. Intraluminal EVT occludes spiral arterioles to maintain a low oxygen tension environment that is requisite for normal early placental and fetal development. Towards the end of the first trimester, low resistance, high capacity flow is restored and the placental intravillous space is perfused with the maternal blood thus establishing effective materno-fetal exchange.

Factors that compromize trophobast cell (both cytotrophoblast (CT) and EVT) function during this critical period of development may dramatically effect subsequent fetal growth, outcome of pregnancy and the life-long disease risk profile of the newborn [6], [7]. EVT migration is affected by oxygen tension [8], [9]. Perturbation of intrauterine oxygen tensions, therefore, may compromise normal placental development. The molecular mechanisms by which oxygen tension regulates EVT function and cell-to-cell communication with maternal tissues remain to be fully elucidated.

Recently, the role of exosomes in cell-to-cell communication has been established [10][13]. Exosomes are nanoparticles (40–100 nm) membrane vesicles that are released following the exocytotic fusion of multi-vesicular bodies with the cell membrane[14]. They have been identified in plasma under both normal and pathological conditions [15] and their concentration increases with disease severity and/or progression [16], and in response to oxidative stress [17].

Recently, we demonstrated that exosomes are released from first trimester placental mesenchymal stem cells (pMSC) and increases endothelial cell migration and vascular tube formation [10]. In addition, the release of exosomes from pMSC was increased under low oxygen tension. These data are consistent with the hypothesis that in response to changes in the environmental milieu (such as oxygen tension) placental cells release exosomes that modify the phenotype of recipient cells. The role of cytotrophoblast cell-derived exosome in cell-to-cell communication and, in particular, their effect on EVT has yet to be established. Similarly, the effect of oxygen tension on the release and bioactivity of cytotrophoblast exosomes is not known.

The aim of this study was to test the hypotheses that: (i) exosomes released by cytotrophoblast cells (CT) increase EVT proliferation and invasion; and (ii) the bioactivity and protein content of CT-derived exosomes is altered by oxygen tension. An in vitro treatment/control experimental design was used to test these hypotheses. Exosomes were isolated from primary first trimester placental villous CT. A first trimester EVT cell line (HTR-8/SVneo) was used to assess the effect of CT-derived exosomes on cell proliferation, invasion and bioactivity. The data obtained in this study are consistent with the hypothesis that exosomes from first trimester CT promote HTR-8/SVneo invasion and proliferation, and exosomal protein content is oxygen tension dependent.

Material and Methods

First trimester sample collection

Tissue collection was approved by the Human Research Ethics Committees of the Royal Brisbane and Women's Hospital, and the University of Queensland (HREC/09/QRBW/14). Written informed consent was obtained from women for the use of placental tissue for research purposes after clinically indicated termination of pregnancy in compliance with national research guidelines. All experimental procedures were conducted within an ISO17025 accredited (National Association of Testing Authorities, Australia) research facility. All data were recorded within a 21 CRF part 11 compliant electronic laboratory notebook (Irisnote, Redwood City, CA, USA).

Isolation of cytotrophoblast cells

First-trimester cytotrophoblast cells (CTs) were isolated from placentae (8–12 weeks) derived by the legal termination of pregnancy (n = 6 biological samples and 2 independent duplicate cultures per placenta) as previously described [18]. Briefly, 10–20 g of chorionic villi were washed in phosphate buffer saline (PBS) and were subjected to three sequential treatments with digestion buffer (0.25% trypsin (Gibco® Trypsin, Life Technologies™, Carlsbad, CA) and 0.1 mg of DNase I (Sigma-Aldrich™, Saint Louis, USA) per ml in HBSS (1x) + HEPES (25 mM). After each 15 min step, the supernatant fluid was layered over fetal calf serum (25 ml supernatant over 5 ml FCS). The supernatant fluid was centrifuged at 400× g for 10 min and the cell pellet was suspended in Dulbecco's modified Eagle's medium (DMEM) (Life Technologies™, Carlsbad, CA). A total of 6 ml of DMEM containing cytotrophoblast cells were layered onto a pre-formed colloidal silica gradient (Percoll, 10–70% (GE Healthcare Life Sciences, Piscataway NY, USA) diluted in HBSS 1X (Life Technologies™, Carlsbad, CA) and centrifuged at 500× g for 30 min. Cytotrophoblast cells displayed a buoyant density of 1.048 to 1.062 g/ml. Cells were collected and washed in 30 ml of DMEM plus 5 ml of FCS. CTs were further isolated by negative selection for monoclonal anti-HLA-A, B, C (clone W6/32, Accurate Chemical and Scientific Corp, Westbury, NY, USA) and negative selection for monoclonal anti-CD45 (Sigma-Aldrich) using magnetic beads (Dynabeads M450, Life Technologies) and characterized by specific markers: anti-cytokeratin-7 (clone 7H8C4, Sigma-Aldrich) and anti-vimentin (clone V9, Sigma-Aldrich).

Isolation and characterization of cytotrophoblast-derived exosomes

Isolation

Exosomes were isolated from CT-conditioned incubation medium as previously described [10], [19]. In brief, CT-conditioned media was centrifuged at 300× g for 15 min, 2,000× g for 30 min, and 12,000× g for 45 min to remove whole cells, and debris. The resultant supernatant fluid was passed through a 0.22 µm sterile filter (Steritop™, Millipore, Billerica, MA, USA) and then centrifuged at 100,000× g for 75 min (Thermo Fisher Scientific Ins., Asheville, NC, USA, Sorvall, SureSpinTM 630/36, Tube angle: 900). The pellet was resuspended in PBS, washed and re-centrifuged (100,000× g for 75 minutes). The pellet was resuspended in PBS, layered on a continuous sucrose gradient (0.25–2 mM sucrose) (Sigma-Aldrich) prepared using a Hoefer SG30 gradient maker (GE Healthcare, NSW, Australia) and centrifuged at 110,000 g for 20 h. Fractions (10 in total) were collected with an 18-G needle and the density of each fraction was determined using the refraction index with OPTi digital refractometer (Bellingham+Stanley Inc., Lawrenceville, GA, USA). Fraction were diluted in PBS, and then centrifuged at 110,000× g for 70 min. Recovered exosomes pellet was resuspended in 50 µl PBS and their protein concentration determined by the dye-binding assay [19].

Exosome protein quantification

Exosome-containing fractions (1.146 to 1.199 g/ml) from sucrose gradients were combined in a single tube and centrifuged at 110,000× g for 70 min. Exosome pellets were resuspended in 50 µl PBS and their proteins determined by the DC™ Protein Assay (BIO-RAD, Hercules, CA, USA). Briefly, exosome samples (5 µl) were prepared by adding RIPA buffer (50 mM Tris, 1% Triton ×100, 0.1% SDS, 0.5% DOC, 1 mM EDTA, 150 mM NaCl, protease inhibitor) directly to exosomes suspended in PBS and sonicated at 37°C for 15 s three times to lyse exosome membrane and solubilize the proteins. Bovine serum albumin (BSA) diluted in RIPA buffer and PBS mixture (1∶1) was prepared as protein standards (0, 200, 400, 600, 800, 1,000, 1,500 µg/mL). Standards and samples (exosomes) were transferred to 96-well plates. Alkaline copper tartrate solution (BIO-RAD, USA) and dilute Folin Reagent (BIO-RAD, USA) were added to the samples and incubated for 15 min. The absorbance was read at 750 nm with the Paradigm Detection Platform (Beckman Coulter, USA).

Western Blot

Protein from each sucrose gradient fraction (10 in total) obtained after exosome isolation were separated by polyacrylamide gel electrophoresis, transferred to Immobilon-®FL polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA) and probed with primary mouse monoclonal anti-CD63 (1∶2000; ab8219, Abcam, Sapphire Bioscience Pty Ltd, NSW, Australia), anti-CD81 (1∶1500, MAB6435, Abnova, Tapei City, Taiwan), anti-CD9 (1∶1,500; ab2215, Abcam, Sapphire Bioscience) and anti- Placental Alkaline Phosphatase (PLAP; 1∶1000; ab96588, Abcam, Sapphire Bioscience), as previously described [19], [20] exosome specific markers. Membranes were washed in Tris buffer saline and incubated (1 h) in TBST/0.2% BSA containing horseradish peroxidase– conjugated goat anti-mouse antibody. Proteins were detected by enhanced chemiluminescence with using a SRX-101A Tabletop Processor (Konica Minolta, Ramsey, NJ, USA). Bands densitometry ratio was determined using the GS-800 Calibrated Densitometer (Bio-Rad Laboratories, Hercules, CA, USA).

Transmission electron microscopy

Exosomes isolated by differential and continuous sucrose gradient centrifugation were analyzed by transmission electron microscopy. Exosome pellets (as described above) were fixed in 3% (w/v) glutaraldehyde and 2% paraformaldehyde in cacodylate buffer, pH 7.3. 5 µl of sample was then applied to a continuous carbon grid and negatively stained with 2% uranyl acetate. The samples were examined in an FEI Tecnai 12 transmission electron microscope (FEI™, Hillsboro, Oregon, USA).

Effect of oxygen tension on exosome release

The effects of oxygen tension on the release of exosomes from CTs were assessed by incubating cells for 48 h in exosome-free culture medium (culture media was depleted of the contaminating exosomes using the same protocol for exosome isolation described previously and exosome-free culture media medium was confirmed by electron microscope) under an atmosphere of 5% CO2-balanced N2 to obtain 1%, 3% or 8% O2 (pO2 ∼6.75, ∼20.25 or ∼54 mmHg, respectively, n = 6 biological replicates in duplicate) in an automated PROOX 110-scaled hypoxia chamber (BioSpherics™, Lacona, NY, USA). The three-compartment hypoxia chamber allowed the simultaneous analysis of CT-cells from individual placentae thus reducing inter-assay variation. Cell viability was determined by Trypan Blue exclusion and Countess® Automated cell counter (Life Technologies™). In all experiments, viability remained at >95% and was not significantly different between groups (p = 0.85). Incubation media pO2 and pH were independently confirmed using a blood gas analyzer (Radiometer®, Brønshøj, Denmark) and NeoFox oxygen probe (Ocean Optics ™, Dunedin, FL, USA).

Effect of exosomes on extra-villous trophoblast cell invasion and proliferation

A first trimester cell line (HTR-8/SVneo) was used to establish the effects of CT-derived exosomes on cell invasion. HTR-8/SVneo cells were kindly donated by Dr Charles H. Graham (Queen's University, Ontario, Canada) [21], [22]. The cells were cultured in RPMI-1640 (HyClone, South Logan, USA) supplemented with 10% FCS, 100 U/ml penicillin, and 100 µg/ml streptomycin (HyClone), at 37°C and 5% CO2. Before experiments, HTR-8/SVneo cells were cultured in RPMI-1640 supplemented with 0.2% FBS in 96-well culture plate (Corning Life Science, Tewksbury, MA, USA) according to the manufacturer's instructions for 18–24 h. During experiments, cells were visualized using a real-time cell imaging system (IncuCyte™ live-cell ESSEN BioScience Inc, Ann Arbor, Michigan, USA) and were imaged every 1–2 h to monitor treatment-induced effects on cell invasion. Time course and dose response effects were established using exosomes released from CTs incubated under 1% O2 for up to 48 h.

Time Course

To determine the effects of CT-derived exosomes on cell invasion, HTR-8/SVneo cells were incubated in the presence (treatment: 100 µg exosomal protein/ml) or absence (control) of exosomes for up to 24 h (n = 12). Cell invasion was monitored by scratch assays [10]. A scratch was made on confluent monolayers using a 96-pin WoundMaker™ (BioScience Inc, Ann Arbor, Michigan, USA) and layered with 3 mg/ml collagen type I (Life Technologies™, Carlsbad, CA) and incubated at 37°C for 30 min to create a 3D matrix-gel. Wound images were automatically acquired and registered by the IncuCyteTM software system. CellPlayer™ 96-Well Invasion Assay software was use to fully automate data collection. Data were processed and analyzed using IncuCyte™ 96-Well Cell Invasion Software Application Module. Data are presented as the Relative Wound Density (Eizen, v1.0 algorithm). The rate of wound closure was compared using the half-maximal stimulatory time (ST50) and area under the time course curve (AUC)[10].

Dose Response

To assess the effect of exosome concentration on extra-villous trophoblast invasion and proliferation, HTR-8/SVneo cells were cultured in the presence of increasing exosomes concentration (5, 10, 20, 50 and 100 µg exosomal protein/ml) for 24 h. Data are presented as half-maximal effective concentration (EC50).

Effects of oxygen tension on CT-derived exosome bioactivity

To determine the effect of oxygen tension on exosome bioactivity, exosomes were obtained from CTs incubated under 1%, 3% and 8% O2 (as detailed above) for 24 h. The effects of exosomes on HTR-8/SVneo cell invasion and proliferation were assessed as detailed above.

Proliferation

Cell proliferation was measured by the change in confluence in the presence of exosomes (100 µg exosomal protein/ml) isolated from 1%, 3% and 8% O2 using a standard confluence algorithm (IncuCyte™) as we have previously published[10], [23].

Proteomic analysis of cytotrophoblast derived-exosomes by mass spectrometry (MS)

Isolated exosomes were solubilized in 8 M urea in 50 mM ammonium bicarbonate, pH 8.5, and reduced with DTT for 1 h. Proteins were then alkylated in 10 mM iodoacetic acid (IAA) for 1 h in the dark. The sample was diluted to 1∶10 with 50 mM ammonium bicarbonate and digested with trypsin (20 µg) at 37°C for 18 h. The samples were desalted by solid phase extraction using a STAGE tip protocol (Stop and go extraction tips for matrix-assisted laser desorption/ionization, nano-electrospray, and LC/MS sample pre-treatment in proteomics). The eluted peptides were dried by centrifugal evaporation to remove acetonitrile and redissolved in Solvent A. The resulting peptide mixture was analysed by Liquid Chromatography (LC)/Mass Spectrometry (MS) LC-MS/MS on a 5600 Triple TOF mass spectrometer (AB Sciex, Framingham, U.S.A.) equipped with an Eksigent Nanoflow binary gradient HPLC system and a nanospray III ion source. Solvent A was 0.1% formic acid in water and solvent B was 0.1% formic acid in acetonitrile. MS/MS spectra were collected using Information Dependent Acquisition (IDA) using a survey scan (m/z 350–1500) followed by 25 data-dependent product ion scans of the 25 most intense precursor ions. All mass spectra were analysed using the Mascot and Protein Pilot search engines against the Swissprot-swissprot database with the species set as human (scores greater than 30). False discovery rate (FDR) was estimated using a reversed sequence database. Finally, proteins identified were submitted to bioinformatic pathway analysis (Ingenuity Pathway Analysis [IPA]; Ingenuity Systems, Mountain View, CA; www.ingenuity.com).

Statistical Analysis

Data are represented as mean ± SEM, with n = 6-12 different cell cultures of CTs isolated from first trimester pregnancies. Comparisons between two group means were performed by unpaired Student's t-test. Multiple groups were compared using the analysis of variance (ANOVA) post hoc analyses were used for pair-wize comparisons (Bonferroni correction test). Statistical significance was defined as p<0.05.

Results

Characterization of cytotrophoblast-derived exosomes

Characterization included analysis of the physical properties of exosomes on a continuous sucrose gradient and protein composition by Western blot. CD63, CD9, CD81 and PLAP positive nano-paticles displayed a buoyant density of 1.146 – 1.199 g/ml (Figure 1A). Each exosome-containing fraction (5 to 8) was separated by SDS-PAGE and stained with SimplyBlue™ SafeStain (Invitrogen). Fractions 5 to 8 displayed a similar protein profile that was distinct from that observed for cytotrophoblast total cellular protein (Figure 1B). The exosomal fractions isolated from CTs were pooled and examined under transmission electron microscopy. Exosomes where identified as vesicles sized between 40–100 nm (Figure 1C).

Figure 1. Detection and characterization of Cytotrophoblast cell-derived exosomes.

Figure 1

Cytotrophoblast cells were isolated from chorionic villi obtained from first trimester pregnancies and cultured under different oxygen tension (see Methods). Exosomes were isolated from CTs culture media and characterized morphologically and using specific marker for exosome proteins. (A) Representative Western blot for exosome markers: CD63, CD9, CD81 and PLAP. Sample loading was normalized by protein content. Fractions 1 to 10, represent fractions collected after buoyant density centrifugation. (B) Protein profile of exosomal proteins and cytotrophoblast cells proteins. Exosomal proteins derived from fraction 5 to 8 (positive for exosomal marker) and cellular proteins of trophoblast cells (cells) were separated by SDS-PAGE and stained with SimplyBlueTM SafeStain. (C) Electron micrograph of exosomes isolated by ultracentrifuge and purified with a sucrose gradient (pooled exosomal pellet) from cytotrophoblast cells. In B, Scale bar 100 nm. In A, B and C, none of the experiments performed were significantly different using different oxygen tension.

Effects of oxygen tension on exosome release

The release of exosomes (µg exosomal protein/106 cell/48 h) from CTs was simultaneously assessed at 1%, 3% and 8% O2 using a 3-compartment hypoxia chamber and presented in Figure 2. At 1%, 3% and 8% O2, exosomal protein release averaged 0.32±0.04, 0.19±0.02 and 0.11±0.01 µg protein/106 cells/48 h respectively (ANOVA, p<0.0001, n = 6 in duplicate). Post-hoc tests (Bonferroni's multiple comparison test) identified significant differences between all group means (p<0.05). Cell viability (>95%) and incubation medium pH at 48 h displayed no significant treatment effects (p = 0.80). Incubation chamber oxygen tensions were independently monitored and verified.

Figure 2. Exosomes released from cytotrophoblast cell exposed to different oxygen tension.

Figure 2

Effects of oxygen tension on the release of exosomes from cytotrophoblast cells are presented as ug exosomal protein/106/48 h. Data are presented as a scatter plot with mean ± SEM (n = 6 biological samples and 2 independent duplicate cultures per placenta duplicate). ***p<0.001 versus 8% O2; **p<0.01 versus 1% O2; †p<0.05 versus 3% O2.

CTs-derived exosomes induce EVT invasion

Time course

Representative photomicrographs of HTR-8/Svneo wound closure for treatment and control experiments are presented in Figure 3A. The effect of CT-derived exosomes on HTR-8/SVneo cell invasion is presented as relative wound density (percent) over time (Figure 3 B). The rate of wound closure was significantly increased in the presence of CT-derived exosomes as measured by ST50 (9.4±0.4 versus 3.2±0.2, p<0.001) and area under the curves (1333±74 versus 2108±122, p<0.001). The effect of exosomes was concentration dependent (Figure 3C).

Figure 3. Cytotrophoblast cell-derived exosomes increased EVT invasion.

Figure 3

EVT cells were grown to confluence in complete media. A wound was made using 96 well WoundMaker and then overlaid to form a 3D matrix-gel (see Methods). EVT invasion was measured in absence (white circles) or presence (black circles) of 100 ug/ml of exosomes from cytotrophoblast cells exposed to 1% O2 (exo-CTs-1%) for 24 h. (A) Top: a, Wound imaged immediately after wounding; b, Graphical representation from a showing the calculation of initial wound width (black); c and e, Image at the midpoint of the experiment; d and f, Graphical representation from c and e of cell invasion (gray) at the midpoint of the experiment. (B) Time course of wound closure for HTR8/SVneo expressed as relative wound density (%). Data are presented as mean ± SEM for control (no exosomes, open circles) and treatment (100 µg/ml exosomal protein, closed circles). (C) Dose response curve for the effect of CT-derived exosomes on HTR8/SVneo invasion. Data are presented as a non-linear regression analysis (curve fit) and mean ± SEM.

Dose Response

The effect of increasing concentrations of CT-derived exosomes on EVT invasion is presented in Figure 4. Exosomes significantly increased HTR-8/SVneo cell invasion and proliferation in a concentration-dependent manner. For cell invasion, EC50 = 29.4±2.1, 47.8±3.2 and 81.8±6.1 µg/ml for treatment in presence of exosomes isolated from 1%, 3% and 8% O2, respectively (p<0.005).

Figure 4. Effect of oxygen tension on exosome bioactivity.

Figure 4

EVT cell invasion was measurement in presence of exosomes isolated from cytotrophoblast cells exposed to three different oxygen tension (1%, 3% and 8% O2). (A) The graph represents the changes of half-maximal effective concentration (EC50) and (B) half-maximal stimulatory time (ST50) exosomes on EVT invasion in response to oxygen tension (source). Values are mean ± SEM. *p<0.01 versus all conditions; †p<0.05 versus 8% O2.

Effect of oxygen tension on CT-derived exosome bioactivity

In this study, exosome bioactivity was defined as the half maximal effect of exosome on EVT invasion (half-maximal stimulatory time (ST50) and half-maximal effective concentration (EC50)). Exosomes isolated from CTs exposed to 3% (exo-CTs-3%) and 8% O2 (exo-CTs-8%) increased the EC50 on EVT invasion ∼1.6-fold and ∼2.7-fold compared to exo-CTs-1%, respectively (Figure 4A). The effect of different oxygen tension on bioactivity of exosomes was correlated with an increase in the ST50 (∼1.5-fold and ∼2.4-fold with exo-CT-3% and exo-CTs-8%, respectively) compared to effect on EVT invasion in presence of exo-CTs-1% (Figure 4B).

CTs-derived exosomes increase EVT proliferation

A real-time imaging system (IncuCyte™) was used to measure cell proliferation using non-label cell monolayer confluence approach. The proliferation ratio (+exosomes/-exosomes for each hour) was significantly higher (p<0.05) compared to the control in the absence of exosomes (Figure 5). At 24 hours, exo-CTs-1% increased EVT proliferation by ∼1.5 fold compared to those in absence of exosomes (control).

Figure 5. Effect of cytotrophoblast cell-derived exosomes on EVT proliferation.

Figure 5

EVT cell proliferation was measurement in presence of exosomes (100 µg/ml) isolated from cytotrophoblast cells exposed to three different oxygen tension (1%, 3% and 8% O2). Values are mean ± SEM. *p<0.01 versus control (-exo-CTs) for each time point.

Proteomic analysis of CTs-derived exosomes

Mass spectrometry analysis identified over 160 exosomal proteins (Table 1). We identified unique proteins for each condition (Figure 6). The biological relevance of differentially expression proteins was analyzed using Ingenuity Pathway Analysis (IPA) software. Exosomal proteins isolated from CT exposed to different oxygen tensions were associated with cellular movement and morphology, immune cell trafficking and cellular assembly and organization in accordance with IPA analysis. The canonical pathways associated with our exosomal proteins defined by IPA Core comparison analysis showed that the score (-log [p-value]) for proteins associated with HIF-α signalling (Figure 6B) and IL-8 signalling (Figure 6C) were inversely correlated to oxygen tension. Finally, we investigated the molecular network that can be activated by the unique proteins identified in exosomes isolated from cytotrophoblast cells exposed to 1% O2 (31 proteins) (Figure 7). We found molecules involved in cellular movement such as MMP9, TGF-β, P38 MAPK, VEGF and others.

Table 1. List of proteins identified in exosomes from CT exposed to different oxygen level.

1% O2
Protein ID Symbol Entrez Gene Name Location Type(s)
ABHD8_HUMAN ABHD8 abhydrolase domain containing 8 unknown enzyme
ACTN1_HUMAN ACTN1 actinin, alpha 1 Cytoplasm other
PLCA_HUMAN AGPAT1 1-acylglycerol-3-phosphate O-acyltransferase 1 (lysophosphatidic acid acyltransferase, alpha) Cytoplasm enzyme
ALBU_HUMAN ALB albumin Extracellular Space transporter
ANXA1_HUMAN ANXA1 annexin A1 Plasma Membrane other
ANX11_HUMAN ANXA11 annexin A11 Nucleus other
ANXA2_HUMAN ANXA2 annexin A2 Plasma Membrane other
APOA1_HUMAN APOA1 apolipoprotein A-I Extracellular Space transporter
CO3_HUMAN C3 complement component 3 Extracellular Space peptidase
CO9_HUMAN C9 complement component 9 Extracellular Space other
CO4A1_HUMAN COL4A1 collagen, type IV, alpha 1 Extracellular Space other
CO4A2_HUMAN COL4A2 collagen, type IV, alpha 2 Extracellular Space other
DHX58_HUMAN DHX58 DEXH (Asp-Glu-X-His) box polypeptide 58 Cytoplasm enzyme
FBLN1_HUMAN FBLN1 fibulin 1 Extracellular Space other
VGFR1_HUMAN FLT1 fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor) Plasma Membrane kinase
FINC_HUMAN FN1 fibronectin 1 Extracellular Space enzyme
FSTL3_HUMAN FSTL3 follistatin-like 3 (secreted glycoprotein) Extracellular Space other
G3P_HUMAN GAPDH glyceraldehyde-3-phosphate dehydrogenase Cytoplasm enzyme
VTDB_HUMAN GC group-specific component (vitamin D binding protein) Extracellular Space transporter
HBB_HUMAN HBB hemoglobin, beta Cytoplasm transporter
HBD_HUMAN HBD hemoglobin, delta Cytoplasm transporter
H2B1B_HUMAN HIST1H2BB histone cluster 1, H2bb Nucleus other
PGBM_HUMAN HSPG2 heparan sulfate proteoglycan 2 Plasma Membrane enzyme
HTRA4_HUMAN HTRA4 HtrA serine peptidase 4 unknown other
INS_HUMAN INS insulin Extracellular Space other
ITIH4_HUMAN ITIH4 inter-alpha-trypsin inhibitor heavy chain family, member 4 Extracellular Space other
ITM2B_HUMAN ITM2B integral membrane protein 2B Plasma Membrane other
K2C1_HUMAN KRT1 keratin 1 Cytoplasm other
K1C10_HUMAN KRT10 keratin 10 Cytoplasm other
K1C18_HUMAN KRT18 keratin 18 Cytoplasm other
K1C19_HUMAN KRT19 keratin 19 Cytoplasm other
K2C7_HUMAN KRT7 keratin 7 Cytoplasm other
K2C8_HUMAN KRT8 keratin 8 Cytoplasm other
LG3BP_HUMAN LGALS3BP lectin, galactoside-binding, soluble, 3 binding protein Plasma Membrane transmembrane receptor
MMP12_HUMAN MMP12 matrix metallopeptidase 12 (macrophage elastase) Extracellular Space peptidase
MMP2_HUMAN MMP2 matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) Extracellular Space peptidase
MMP9_HUMAN MMP9 matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) Extracellular Space peptidase
MS4A7_HUMAN MS4A7 membrane-spanning 4-domains, subfamily A, member 7 unknown other
MYH9_HUMAN MYH9 myosin, heavy chain 9, non-muscle Cytoplasm transporter
NCTR1_HUMAN NCR1 natural cytotoxicity triggering receptor 1 Plasma Membrane transmembrane receptor
SLIP_HUMAN NUGGC nuclear GTPase, germinal center associated Nucleus other
NXF1_HUMAN NXF1 nuclear RNA export factor 1 Nucleus transporter
PLGF_HUMAN PGF placental growth factor Extracellular Space growth factor
PLXB2_HUMAN PLXNB2 plexin B2 Plasma Membrane transmembrane receptor
POTEE_HUMAN POTEE/POTEF POTE ankyrin domain family, member F unknown other
PRG2_HUMAN PRG2 proteoglycan 2, bone marrow (natural killer cell activator, eosinophil granule major basic protein) Extracellular Space other
PSA2_HUMAN PSMA2 proteasome (prosome, macropain) subunit, alpha type, 2 Cytoplasm peptidase
PSA6_HUMAN PSMA6 proteasome (prosome, macropain) subunit, alpha type, 6 Cytoplasm peptidase
PSA7_HUMAN PSMA7 proteasome (prosome, macropain) subunit, alpha type, 7 Cytoplasm peptidase
PSB2_HUMAN PSMB2 proteasome (prosome, macropain) subunit, beta type, 2 Cytoplasm peptidase
PSB7_HUMAN PSMB7 proteasome (prosome, macropain) subunit, beta type, 7 Cytoplasm peptidase
QSOX1_HUMAN QSOX1 quiescin Q6 sulfhydryl oxidase 1 Cytoplasm enzyme
S10AB_HUMAN S100A11 S100 calcium binding protein A11 Cytoplasm other
PAI1_HUMAN SERPINE1 serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 Extracellular Space other
GDN_HUMAN SERPINE2 serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2 Extracellular Space other
SMCA1_HUMAN SMARCA1 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1 Nucleus transcription regulator
SYC2L_HUMAN SYCP2L synaptonemal complex protein 2-like Nucleus other
TRFE_HUMAN TF transferrin Extracellular Space transporter
TFPI1_HUMAN TFPI tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) Extracellular Space other
TSP1_HUMAN THBS1 thrombospondin 1 Extracellular Space other
TIMP1_HUMAN TIMP1 TIMP metallopeptidase inhibitor 1 Extracellular Space other
TINAL_HUMAN TINAGL1 tubulointerstitial nephritis antigen-like 1 Extracellular Space transporter
TMEM5_HUMAN TMEM5 transmembrane protein 5 Plasma Membrane other
TRRAP_HUMAN TRRAP transformation/transcription domain-associated protein Nucleus transcription regulator
VAT1_HUMAN VAT1 vesicle amine transport protein 1 homolog (T. californica) Plasma Membrane transporter
WNT7A_HUMAN WNT7A wingless-type MMTV integration site family, member 7A Extracellular Space cytokine
YIPF1_HUMAN YIPF1 Yip1 domain family, member 1 Cytoplasm other
3% O2
Protein ID Symbol Entrez Gene Name Location Type(s)
ABHD8_HUMAN ABHD8 abhydrolase domain containing 8 unknown enzyme
ACTB_HUMAN ACTB actin, beta Cytoplasm other
ACTN1_HUMAN ACTN1 actinin, alpha 1 Cytoplasm other
PLCA_HUMAN AGPAT1 1-acylglycerol-3-phosphate O-acyltransferase 1 (lysophosphatidic acid acyltransferase, alpha) Cytoplasm enzyme
ALBU_HUMAN ALB albumin Extracellular Space transporter
ASB18_HUMAN ASB18 ankyrin repeat and SOCS box containing 18 unknown other
BPTF_HUMAN BPTF bromodomain PHD finger transcription factor Nucleus transcription regulator
CO4A_HUMAN C4B (includes others) complement component 4B (Chido blood group) Extracellular Space other
CALI_HUMAN CCIN calicin Cytoplasm other
CGHB_HUMAN CGB (includes others) chorionic gonadotropin, beta polypeptide Extracellular Space other
CO4A1_HUMAN COL4A1 collagen, type IV, alpha 1 Extracellular Space other
CTND1_HUMAN CTNND1 catenin (cadherin-associated protein), delta 1 Nucleus other
VGFR1_HUMAN FLT1 fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor) Plasma Membrane kinase
FINC_HUMAN FN1 fibronectin 1 Extracellular Space enzyme
VTDB_HUMAN GC group-specific component (vitamin D binding protein) Extracellular Space transporter
HBD_HUMAN HBD hemoglobin, delta Cytoplasm transporter
H2B1B_HUMAN HIST1H2BB histone cluster 1, H2bb Nucleus other
HTRA4_HUMAN HTRA4 HtrA serine peptidase 4 unknown other
INS_HUMAN INS insulin Extracellular Space other
KIF3C_HUMAN KIF3C kinesin family member 3C Cytoplasm other
K1C18_HUMAN KRT18 keratin 18 Cytoplasm other
K2C8_HUMAN KRT8 keratin 8 Cytoplasm other
LG3BP_HUMAN LGALS3BP lectin, galactoside-binding, soluble, 3 binding protein Plasma Membrane transmembrane receptor
MMP12_HUMAN MMP12 matrix metallopeptidase 12 (macrophage elastase) Extracellular Space peptidase
MMP2_HUMAN MMP2 matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) Extracellular Space peptidase
RM43_HUMAN MRPL43 mitochondrial ribosomal protein L43 Cytoplasm translation regulator
NEUL_HUMAN NLN neurolysin (metallopeptidase M3 family) Cytoplasm peptidase
NXF1_HUMAN NXF1 nuclear RNA export factor 1 Nucleus transporter
PLXB2_HUMAN PLXNB2 plexin B2 Plasma Membrane transmembrane receptor
GDN_HUMAN SERPINE2 serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2 Extracellular Space other
SNPH_HUMAN SNPH syntaphilin Plasma Membrane other
SYC2L_HUMAN SYCP2L synaptonemal complex protein 2-like Nucleus other
TRFE_HUMAN TF transferrin Extracellular Space transporter
TFPI1_HUMAN TFPI tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) Extracellular Space other
TSP1_HUMAN THBS1 thrombospondin 1 Extracellular Space other
VAT1_HUMAN VAT1 vesicle amine transport protein 1 homolog (T. californica) Plasma Membrane transporter
WNT7A_HUMAN WNT7A wingless-type MMTV integration site family, member 7A Extracellular Space cytokine
8% O2
Protein ID Symbol Entrez Gene Name Location Type(s)
A2MG_HUMAN A2M alpha-2-macroglobulin Extracellular Space transporter
ABHD8_HUMAN ABHD8 abhydrolase domain containing 8 unknown enzyme
ADH7_HUMAN ADH7 alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide Cytoplasm enzyme
ALBU_HUMAN ALB albumin Extracellular Space transporter
ANR17_HUMAN ANKRD17 ankyrin repeat domain 17 Nucleus other
ANXA1_HUMAN ANXA1 annexin A1 Plasma Membrane other
APOA1_HUMAN APOA1 apolipoprotein A-I Extracellular Space transporter
ASB18_HUMAN ASB18 ankyrin repeat and SOCS box containing 18 unknown other
AT2B1_HUMAN ATP2B1 ATPase, Ca++ transporting, plasma membrane 1 Plasma Membrane transporter
CO3_HUMAN C3 complement component 3 Extracellular Space peptidase
CO4A_HUMAN C4B (includes others) complement component 4B (Chido blood group) Extracellular Space other
CF118_HUMAN C6orf118 chromosome 6 open reading frame 118 unknown other
CGHB_HUMAN CGB (includes others) chorionic gonadotropin, beta polypeptide Extracellular Space other
CO4A1_HUMAN COL4A1 collagen, type IV, alpha 1 Extracellular Space other
CRBA4_HUMAN CRYBA4 crystallin, beta A4 unknown other
EF1A1_HUMAN EEF1A1 eukaryotic translation elongation factor 1 alpha 1 Cytoplasm translation regulator
EVC_HUMAN EVC Ellis van Creveld syndrome Cytoplasm other
EZRI_HUMAN EZR ezrin Plasma Membrane other
FBLN1_HUMAN FBLN1 fibulin 1 Extracellular Space other
VGFR1_HUMAN FLT1 fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor) Plasma Membrane kinase
FMN1_HUMAN FMN1 formin 1 Plasma Membrane other
FINC_HUMAN FN1 fibronectin 1 Extracellular Space enzyme
GKN1_HUMAN GKN1 gastrokine 1 Extracellular Space growth factor
HBB_HUMAN HBB hemoglobin, beta Cytoplasm transporter
HBD_HUMAN HBD hemoglobin, delta Cytoplasm transporter
H2B1B_HUMAN HIST1H2BB histone cluster 1, H2bb Nucleus other
HEMO_HUMAN HPX hemopexin Extracellular Space transporter
ILF3_HUMAN ILF3 interleukin enhancer binding factor 3, 90kDa Nucleus transcription regulator
INS_HUMAN INS insulin Extracellular Space other
ITIH4_HUMAN ITIH4 inter-alpha-trypsin inhibitor heavy chain family, member 4 Extracellular Space other
KI13A_HUMAN KIF13A kinesin family member 13A Cytoplasm transporter
KIF3C_HUMAN KIF3C kinesin family member 3C Cytoplasm other
K2C1_HUMAN KRT1 keratin 1 Cytoplasm other
K1C18_HUMAN KRT18 keratin 18 Cytoplasm other
K2C8_HUMAN KRT8 keratin 8 Cytoplasm other
LG3BP_HUMAN LGALS3BP lectin, galactoside-binding, soluble, 3 binding protein Plasma Membrane transmembrane receptor
MMP2_HUMAN MMP2 matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) Extracellular Space peptidase
MYH9_HUMAN MYH9 myosin, heavy chain 9, non-muscle Cytoplasm transporter
SLIP_HUMAN NUGGC nuclear GTPase, germinal center associated Nucleus other
PCLO_HUMAN PCLO piccolo (presynaptic cytomatrix protein) Cytoplasm transporter
PLXB2_HUMAN PLXNB2 plexin B2 Plasma Membrane transmembrane receptor
PRG2_HUMAN PRG2 proteoglycan 2, bone marrow (natural killer cell activator, eosinophil granule major basic protein) Extracellular Space other
PSG3_HUMAN PSG3 pregnancy specific beta-1-glycoprotein 3 Extracellular Space other
RET4_HUMAN RBP4 retinol binding protein 4, plasma Extracellular Space transporter
SEM4G_HUMAN SEMA4G sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4G Plasma Membrane other
ANT3_HUMAN SERPINC1 serpin peptidase inhibitor, clade C (antithrombin), member 1 Extracellular Space other
GDN_HUMAN SERPINE2 serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2 Extracellular Space other
SNPH_HUMAN SNPH syntaphilin Plasma Membrane other
SYC2L_HUMAN SYCP2L synaptonemal complex protein 2-like Nucleus other
TRFE_HUMAN TF transferrin Extracellular Space transporter
TSP1_HUMAN THBS1 thrombospondin 1 Extracellular Space other
YI016_HUMAN TUBBP5 tubulin, beta pseudogene 5 unknown other
VAT1_HUMAN VAT1 vesicle amine transport protein 1 homolog (T. californica) Plasma Membrane transporter
WNT7A_HUMAN WNT7A wingless-type MMTV integration site family, member 7A Extracellular Space cytokine

All mass spectra were analysed using the Mascot and Protein Pilot search engines against the Swissprot-swissprot database with the species set as human (score over 30). Exosomal proteins identified by mass-spectrometry were analyzed with the Ingenuity Pathway Analysis (Ingenuity Systems, www.ingenuity.com). False discovery rate (FDR) was estimated using a reversed sequence database. List of total exosomal protein from cytotrophoblast cells exposed to different oxygen level are presented as Protein ID, Symbol, Entrez Gene Name, Location and type.

Figure 6. Analysis of cytotrophoblast cell-derived exosome proteins.

Figure 6

(A) The Venn diagram represents the distribution of common and unique proteins identified by nanospray LC-MS/MS (ABSciex 5600) in exosomes released from trophoblast cells exposed to 1%, 3% and 8% of oxygen tension. Comparison of canonical pathways: (B) HIFα, and (C) IL-8 signaling identified by IPA core analysis. Values are mean ± SEM. In B and C, *p<0.005 versus all condition; †p<0.05 versus 8% O2.

Figure 7. Ingenuity Pathway Analysis of Exosomal Proteins.

Figure 7

Unique proteins identified in exosomes isolated from cytotrophoblast cells exposed to 1% oxygen were submitted to IPA network analysis. Green: signaling involving in cellular movement.

Discussion

Extravillous trophoblast invasion into the maternal tissue is a critical process in placentation. Hypoxia is a risk factor for complications of pregnancy and may adversely affect placentation and development of the materno-fetal vascular exchange. In particular, during early pregnancy low oxygen tension may impact on EVT migration and interactions with the maternal spiral arterioles [24][26]. Exosomes from cytotrophoblast cells may interact with EVT and modify their invasiveness, however, the effect and role of exosomes from placental cells has yet to be defined. The aim of this study was to establish the effect of oxygen tension on the release and bioactivity of CT-derived exosomes on EVT invasion and proliferation in vitro. The data obtained are consistent with the hypothesis that exosomes released from cytotrophoblast cells incubated under low oxygen tension promote HTR-8/SVneo invasion and proliferation. While the role of CT exosomes in vivo remains to be established, their release under hypoxic conditions within the placenta may be an adaptive response to promote proliferation and invasion of extravillous trophoblast.

In this study, placental cell exosomes were isolated from cell-conditioned media using differential and buoyant density centrifugation according to our previously published method [10]. CT-derived exosomes displayed: a buoyant density between 1.146 and 1.199 g/ml; positive expression for exosome markers, such as CD63, CD9 and CD81; and a diameter of than less 100 nm analysed under electron microscope. These characteristics are consistent with previously published data [15], [27]. The release of exosomes from CTs was measured as total CD63 positive, particulate protein with a buoyant density 1.146 to 1.199 g/ml.

The release of exosomes from CTs was inversely correlated with oxygen tension. When CTs were incubated under 1% oxygen, exosome release into the incubation medium was 3-fold greater than that observed when cells were incubated under 3% and 8% oxygen. This increase in exosome release was not associated with a loss of cell viability. Our observations that exosome release is affected by oxygen tension are consistent with previously published data obtained from other cell types [28][30], including first trimester placental mesenchymal stem cells [10]. While the mechanism(s) by which low oxygen tension increases the release of exosome release remains to be established, oxygen-sensing transcriptional factors, such as HIF-α may be involved [28].

Jauniaux et al., (2000) measured in situ oxygen tension during early pregnancy (at 60 days) within the chorionic placenta, inter-villous space (IVS), and maternal endometrium underlying the placenta [31]. Oxygen tension was ∼3%, 1% and 8%, respectively. Low oxygen tension within the placenta and IVS at this stage of pregnancy may promote the release of exosomes from cytotrophoblast cells and enhance cell-to-cell communication. In particular, exosomes released from CTs may induce functional changes in EVTs that promote cell invasion and proliferation. Consistent with this hypothesis, in this study we demonstrated that CT-derived exosomes increase invasion and proliferation of the EVT cell line HTR-8/SVneo.

During the first trimester of pregnancy, EVT cells invade the decidua and myometrium and regulate the flow of maternal blood into the IVS. EVTs co-localize with maternal spiral arterioles and are present within the lumen of these vessels (where they are thought to prevent flow into the IVS). Subsequent perfusion of the IVS is associated with the transformation of these arterioles from high resistance, low capacity to low resistance, high capacity vessels. EVTs play a role in remodelling these vessels [32], [33]. Abnormal EVT function may result in failure to transform these vessels resulting in compromised placental perfusion and hypoxia [34]. What regulates EVT invasion and/or function and their interactions with maternal vessels remains to be clearly established. The data obtained in this study, however, establish that exosomes released form CTs increase EVT cell invasion in a concentration-dependent manner, and that the activity of exosomes is increased under low oxygen tension.

In this study, HTR-8/SVneo were cultured under low oxygen tension for at least 48 h before experimental manipulation and incubated in the presence of CT-derived exosomes for 24 h. An automated real-time imaging system was used to maintain cells in optimal conditions for quantifying cell invasion and proliferation. Exosome-treatment reduced EVT ST50 compared to control incubations (i.e. absence of exosomes). Furthermore, exosomes isolated from CTs incubated under low oxygen tension (i.e. 1%) displayed greater activity (per unit exosomal protein) than exosomes obtained from cells incubated at higher oxygen tensions (i.e. 3 and 8%). Similar, effects (but of lower magnitude) were observed for EVT cell proliferation.

The effect of low oxygen tension on EVT invasion remains controversial and disparate data have been reported [8], [33], [35], [36]. Studies performed on EVT cells isolated from placental tissue (5 to 10 weeks of gestation) established that low oxygen tension reduces invasion of EVT cells through decreased MMP-2 [36] and appears to be mediated by urokinase plasminogen activator (PLAU) system [8]. In contrast, low oxygen tension (<1% O2) increased HTR-8/SVneo cell invasion when compared to cell incubated under 20% O2 [37].

The data obtained in the current study establish a role for exosomes in the intercellular communication between placental cells and in regulating EVT cell invasion in an oxygen-dependent manner. Low oxygen tension increased exosome release and modified their protein content. When CTs were incubated under different oxygen tensions, exosomal protein content was altered significantly. Ingenuity Pathway Analysis (IPA) of exosomal proteins identified oxygen-dependent changes in HIFα and IL-8 signalling pathways. In addition, when CTs were incubated under low oxygen tension, exosomal proteins identified were predominantly associated with pathways involved in the activation of MMP-9, TGF-β, MAPK, VEGF, p38MAPK, TIMP1 and ERK1/2. It remains to be established whether or not specific changes in exosomal protein content are causally related to changes in EVT invasion and proliferation. EVT cells have a crucial role in placentation, characterized by their invasion of spiral uterine arteries to establish a low-resistance, high-capacity perfusion system. The mechanism involved in EVT invasion is not completely understood, however, there is a consensus that invading EVT cells up-regulate proteins such as MMPs, integrins (α5β1 and α1β1) and VE-cadherin which support uterine wall invasion. Our data suggest that the exosome released from cytotrophoblast cells also promote EVT invasion including the activation of MMPs, MAPK and invasiveness pathways. We are only beginning to develop an understanding of the role of placental-derived exosomes (e.g. cytotrophoblast cells) in early pregnancy events and, in particular, how they might affect the function of key cell-types (e.g. EVT) involved in the development of the placenta and its vascular communication with both mother and fetus.

In summary, the release of exosomes from primary culture of cytotrophoblast cells is oxygen tension-dependent. CT-derived exosomes increase EVT cell invasion and proliferation in a concentration and oxygen-dependent manner. Exosomal protein content is altered in response to oxygen tension, with the enhancement of signals involved in cellular invasion and migration. The release of CT-derive exosomes under hypoxic conditions within the placenta may be an adaptive response to promote proliferation and invasion of extravillous trophoblast cells.

Funding Statement

CS holds a Postdoctoral Fellowship at The University of Queensland Centre for Clinical Research, Brisbane, Australia. GER was in receipt of an NHMRC Principal Research Fellowship. The work described herein was partially funded by a CIEF grant (University of Queensland), a Smart Futures Fund grant (Department of Employment, Economic Development and Innovation, Queensland Government) and a Translating Health Discovery into Clinical Applications SuperScience Award (Department of Industry, Innovation, Science, Research and Tertiary Education, Australian Government). This investigation was supported by CONICYT (ACT-73 PIA, Pasantía Doctoral en el Extranjero BECAS Chile), FONDECYT (1110977). CS holds CONICYT-PhD fellowships and Faculty of Medicine/PUC-PhD fellowships. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1. Burton GJ, Jauniaux E, Charnock-Jones DS (2010) The influence of the intrauterine environment on human placental development. Int J Dev Biol 54: 303–312. [DOI] [PubMed] [Google Scholar]
  • 2. Rodesch F, Simon P, Donner C, Jauniaux E (1992) Oxygen measurements in endometrial and trophoblastic tissues during early pregnancy. Obstet Gynecol 80: 283–285. [PubMed] [Google Scholar]
  • 3. Jauniaux E, Gulbis B, Burton GJ (2003) Physiological implications of the materno-fetal oxygen gradient in human early pregnancy. Reprod Biomed Online 7: 250–253. [DOI] [PubMed] [Google Scholar]
  • 4. Kaufmann P, Black S, Huppertz B (2003) Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod 69: 1–7. [DOI] [PubMed] [Google Scholar]
  • 5. Lyall F (2006) Mechanisms regulating cytotrophoblast invasion in normal pregnancy and pre-eclampsia. Aust N Z J Obstet Gynaecol 46: 266–273. [DOI] [PubMed] [Google Scholar]
  • 6. Jauniaux E, Van Oppenraaij RH, Burton GJ (2010) Obstetric outcome after early placental complications. Curr Opin Obstet Gynecol 22: 452–457. [DOI] [PubMed] [Google Scholar]
  • 7. Barker DJ (2007) The origins of the developmental origins theory. J Intern Med 261: 412–417. [DOI] [PubMed] [Google Scholar]
  • 8. Lash GE, Otun HA, Innes BA, Bulmer JN, Searle RF, et al. (2006) Low oxygen concentrations inhibit trophoblast cell invasion from early gestation placental explants via alterations in levels of the urokinase plasminogen activator system. Biol Reprod 74: 403–409. [DOI] [PubMed] [Google Scholar]
  • 9. Zhao H, Jiang Y, Cao Q, Hou Y, Wang C (2012) Role of integrin switch and transforming growth factor Beta 3 in hypoxia-induced invasion inhibition of human extravillous trophoblast cells. Biol Reprod 87: 47. [DOI] [PubMed] [Google Scholar]
  • 10. Salomon C, Ryan J, Sobrevia L, Kobayashi M, Ashman K, et al. (2013) Exosomal Signaling during Hypoxia Mediates Microvascular Endothelial Cell Migration and Vasculogenesis. PLoS One 8: e68451. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Ludwig AK, Giebel B (2012) Exosomes: small vesicles participating in intercellular communication. Int J Biochem Cell Biol 44: 11–15. [DOI] [PubMed] [Google Scholar]
  • 12. Yang C, Robbins PD (2011) The roles of tumor-derived exosomes in cancer pathogenesis. Clin Dev Immunol 2011: 842849. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Yang M, Chen J, Su F, Yu B, Su F, et al. (2011) Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Mol Cancer 10: 117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Thery C, Zitvogel L, Amigorena S (2002) Exosomes: composition, biogenesis and function. Nat Rev Immunol 2: 569–579. [DOI] [PubMed] [Google Scholar]
  • 15. Mincheva-Nilsson L, Baranov V (2010) The role of placental exosomes in reproduction. Am J Reprod Immunol 63: 520–533. [DOI] [PubMed] [Google Scholar]
  • 16.Redman CW, Sargent IL (2008) Circulating microparticles in normal pregnancy and pre-eclampsia. Placenta 29 Suppl A: S73–77. [DOI] [PubMed] [Google Scholar]
  • 17. Hedlund M, Nagaeva O, Kargl D, Baranov V, Mincheva-Nilsson L (2011) Thermal- and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma T and B cells. PLoS One 6: e16899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Maloyan A, Mele J, Muralimanohara B, Myatt L (2012) Measurement of mitochondrial respiration in trophoblast culture. Placenta 33: 456–458. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Thery C, Amigorena S, Raposo G, Clayton A (2006) Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol Chapter 3 : Unit 3 22. [DOI] [PubMed] [Google Scholar]
  • 20. Mincheva-Nilsson L, Nagaeva O, Chen T, Stendahl U, Antsiferova J, et al. (2006) Placenta-derived soluble MHC class I chain-related molecules down-regulate NKG2D receptor on peripheral blood mononuclear cells during human pregnancy: a possible novel immune escape mechanism for fetal survival. J Immunol 176: 3585–3592. [DOI] [PubMed] [Google Scholar]
  • 21. Graham CH, Hawley TS, Hawley RG, MacDougall JR, Kerbel RS, et al. (1993) Establishment and characterization of first trimester human trophoblast cells with extended lifespan. Exp Cell Res 206: 204–211. [DOI] [PubMed] [Google Scholar]
  • 22. Irving JA, Lysiak JJ, Graham CH, Hearn S, Han VK, et al. (1995) Characteristics of trophoblast cells migrating from first trimester chorionic villus explants and propagated in culture. Placenta 16: 413–433. [DOI] [PubMed] [Google Scholar]
  • 23. Thon JN, Devine MT, Jurak Begonja A, Tibbitts J, Italiano JE Jr (2012) High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1) —mediated inhibition of platelet production. Blood 120: 1975–1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Soares MJ, Chakraborty D, Renaud SJ, Kubota K, Bu P, et al. (2012) Regulatory pathways controlling the endovascular invasive trophoblast cell lineage. J Reprod Dev 58: 283–287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Rosario GX, Konno T, Soares MJ (2008) Maternal hypoxia activates endovascular trophoblast cell invasion. Dev Biol 314: 362–375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Lunghi L, Ferretti ME, Medici S, Biondi C, Vesce F (2007) Control of human trophoblast function. Reprod Biol Endocrinol 5: 6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Lasser C, Eldh M, Lotvall J (2012) Isolation and characterization of RNA-containing exosomes. J Vis Exp: e3037. [DOI] [PMC free article] [PubMed]
  • 28. King HW, Michael MZ, Gleadle JM (2012) Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer 12: 421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Zhang HC, Liu XB, Huang S, Bi XY, Wang HX, et al.. (2012) Microvesicles Derived from Human Umbilical Cord Mesenchymal Stem Cells Stimulated by Hypoxia Promote Angiogenesis Both In Vitro and In Vivo. Stem Cells Dev. [DOI] [PMC free article] [PubMed]
  • 30. Park JE, Tan HS, Datta A, Lai RC, Zhang H, et al. (2010) Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes. Mol Cell Proteomics 9: 1085–1099. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Jauniaux E, Watson AL, Hempstock J, Bao YP, Skepper JN, et al. (2000) Onset of maternal arterial blood flow and placental oxidative stress. A possible factor in human early pregnancy failure. Am J Pathol 157: 2111–2122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Harris LK (2010) Review: Trophoblast-vascular cell interactions in early pregnancy: how to remodel a vessel. Placenta 31 Suppl: S93–98 [DOI] [PubMed] [Google Scholar]
  • 33. Crocker IP, Wareing M, Ferris GR, Jones CJ, Cartwright JE, et al. (2005) The effect of vascular origin, oxygen, and tumour necrosis factor alpha on trophoblast invasion of maternal arteries in vitro. J Pathol 206: 476–485. [DOI] [PubMed] [Google Scholar]
  • 34. Vitoratos N, Hassiakos D, Iavazzo C (2012) Molecular mechanisms of preeclampsia. J Pregnancy 2012: 298343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Genbacev O, Joslin R, Damsky CH, Polliotti BM, Fisher SJ (1996) Hypoxia alters early gestation human cytotrophoblast differentiation/invasion in vitro and models the placental defects that occur in preeclampsia. J Clin Invest 97: 540–550. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Onogi A, Naruse K, Sado T, Tsunemi T, Shigetomi H, et al. (2011) Hypoxia inhibits invasion of extravillous trophoblast cells through reduction of matrix metalloproteinase (MMP)-2 activation in the early first trimester of human pregnancy. Placenta 32: 665–670. [DOI] [PubMed] [Google Scholar]
  • 37. Graham CH, Fitzpatrick TE, McCrae KR (1998) Hypoxia stimulates urokinase receptor expression through a heme protein-dependent pathway. Blood 91: 3300–3307. [PubMed] [Google Scholar]

Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES